Similar articles for PMID: 26709102

Year	Number of Results
1998	2
1999	2
2000	2
2002	3
2003	1
2005	1
2006	2
2007	2
2008	3
2009	3
2010	3
2011	6
2012	13
2013	12
2014	8
2015	7
2016	7
2017	5
2018	9
2019	5
2020	14
2021	11
2022	12
2023	2
2024	0

1

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen DM, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE. Edmondson SD, et al. J Med Chem. 2016 Jan 28;59(2):609-23. doi: 10.1021/acs.jmedchem.5b01372. Epub 2016 Jan 8. J Med Chem. 2016. PMID: 26709102

2

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro GM, Frenkl T, Weber AE, Edmondson SD, Struthers M. Di Salvo J, et al. J Pharmacol Exp Ther. 2017 Feb;360(2):346-355. doi: 10.1124/jpet.116.237313. Epub 2016 Dec 13. J Pharmacol Exp Ther. 2017. PMID: 27965369

3

Vibegron, a Novel Potent and Selective β₃-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.

Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Yoshida M, et al. Eur Urol. 2018 May;73(5):783-790. doi: 10.1016/j.eururo.2017.12.022. Epub 2018 Feb 1. Eur Urol. 2018. PMID: 29366513 Clinical Trial.

4

Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.

Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Minemura K. Yoshida M, et al. BJU Int. 2020 May;125(5):709-717. doi: 10.1111/bju.15020. Epub 2020 Feb 23. BJU Int. 2020. PMID: 31991511 Free PMC article. Clinical Trial.

5

The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.

Shi H, Chen H, Zhang Y, Cui Y. Shi H, et al. Neurourol Urodyn. 2020 Jun;39(5):1255-1263. doi: 10.1002/nau.24387. Epub 2020 May 18. Neurourol Urodyn. 2020. PMID: 32421908

6

Evaluating vibegron for the treatment of overactive bladder.

Rechberger T, Wróbel A. Rechberger T, et al. Expert Opin Pharmacother. 2021 Jan;22(1):9-17. doi: 10.1080/14656566.2020.1809652. Epub 2020 Sep 29. Expert Opin Pharmacother. 2021. PMID: 32993398 Review.

7

International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.

Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Staskin D, et al. J Urol. 2020 Aug;204(2):316-324. doi: 10.1097/JU.0000000000000807. Epub 2020 Feb 18. J Urol. 2020. PMID: 32068484 Clinical Trial.

8

Additive effects of intravenous and intravesical application of vibegron, a β₃-adrenoceptor agonist, on bladder function in rats with bladder overactivity.

Furuta A, Suzuki Y, Igarashi T, Koike Y, Kimura T, Egawa S, Yoshimura N. Furuta A, et al. Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2073-2080. doi: 10.1007/s00210-020-01921-2. Epub 2020 Jun 18. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 32556396

9

Effects of vibegron, a novel β₃-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction.

Maruyama I, Yamamoto S, Tsuchioka K, Yamazaki T. Maruyama I, et al. Eur J Pharmacol. 2020 Jul 5;878:173096. doi: 10.1016/j.ejphar.2020.173096. Epub 2020 Apr 4. Eur J Pharmacol. 2020. PMID: 32259514

10

Vibegron: First Global Approval.

Keam SJ. Keam SJ. Drugs. 2018 Nov;78(17):1835-1839. doi: 10.1007/s40265-018-1006-3. Drugs. 2018. PMID: 30411311

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

117 results

Results by year